The RNA Revolution
RNA has moved from being understood primarily as a messenger molecule to a central target for therapeutic intervention. The success of mRNA vaccines demonstrated that RNA-based medicines can be developed, manufactured, and deployed at unprecedented speed. But vaccines are only the beginning. RNA therapeutics—including siRNA, antisense oligonucleotides, and RNA-targeting small molecules—are being explored for conditions ranging from cancer to rare genetic disorders.
Singapore has recognised that mastering RNA biology and manufacturing is essential to its biomedical ambitions. The National Initiative for RNA Biology and its Applications (NIRBA) opened a 2,000-square-metre research hub at NUS in July 2026, creating dedicated space for RNA innovation, talent development, and biomedical research translation. The hub aligns with Singapore’s Research, Innovation and Enterprise 2030 plan, which has committed S$37 billion to research and innovation over five years, including support for biomedical sciences R&D.
Reading RNA One Molecule at a Time
A fundamental challenge in RNA biology has been understanding how RNA molecules fold and behave. RNA is not a linear string of nucleotides—it bends, folds, and interacts with other molecules, and these structural changes influence how efficiently proteins are produced, how long RNA molecules persist, and how diseases progress. Traditional methods averaged signals across millions of molecules, obscuring the behaviour of individual RNAs.
In May 2026, researchers at A*STAR’s Genome Institute of Singapore developed a new method called sm-PORE-cupine that reads full-length RNA molecules one at a time. The technology combines chemical labelling with nanopore direct RNA sequencing, allowing scientists to see how individual RNA molecules from the same gene can fold differently and behave in distinct ways. This matters because protein production and RNA stability are key components of gene regulation—and when these processes go wrong, they contribute to disease.
The implications extend beyond basic science. Understanding RNA structure at single-molecule resolution could help identify new RNA-based therapeutic targets, support antiviral drug development, and improve disease diagnostics.
Precision Medicine and Asian Genomic Data
Singapore’s precision medicine ambitions are equally ambitious. The PRECISE-SG100K project, which aims to build a comprehensive genomic and health database of 100,000 Singaporeans, has attracted five global pharmaceutical companies as partners: Alnylam, Bayer, Boehringer Ingelheim, Novo Nordisk, and—as of May 2026—GSK. This consortium structure is significant because it gives pharmaceutical companies access to Asian genomic data under a governed framework, while allowing Singapore to retain control over its population’s data.
The strategic logic is clear. Most genomic research has historically focused on European populations, limiting the applicability of findings to Asian populations. By building a multi-ancestry dataset and making it available to industry partners, Singapore positions itself as essential infrastructure for global drug discovery and development.
Manufacturing the Future
RNA therapeutics also require specialised manufacturing capabilities. The Nucleic Acid Therapeutics Initiative, established in 2024, has already supported over 20 industry collaboration projects, and Singapore’s investment in RNA manufacturing capacity is designed to ensure that discoveries made locally can be produced locally. This end-to-end approach—from fundamental RNA biology through to manufacturing scale-up—represents a comprehensive strategy to capture value from the RNA revolution.
Leave a Reply